Alnylam Pharmaceuticals, UK
Maidenhead, UKDownload Project Profile
About the project
Expansion into the UK and EU is one of the goals of Alnylam’s “2020 Initiative.” To that end, in 2016 Hereva supported Alnylam in selecting a site in the UK for its clinical and regulatory groups. A location was identified at Braywick Gate in Maidenhead, about an hour outside of London, and consisted of three floors to be built out in phases.
As Alnylam’s first overseas facility, the chief goal in the design process for Phase 1 was to establish its brand in the UK. Hereva established a team of stakeholders who accomplished this through state-of-the-art design, fully integrated environmental branding and the establishment of recruiting guidelines. Phase 1 was completed in June 2016 to high praise. Anticipating to quickly triple Alnylam’s headcount, Phase 2 began immediately, and was completed by the end of 2016.
Hereva brought years of experience in working on projects in the UK to Alnylam. Challenges for Alnylam included not only the specific design nuances and terminology of working abroad, but also involved the financial requirements for an American company doing business abroad for the first time. Hereva was instrumental in assisting Alnylam in the process of managing design and construction overseas.
About the Client
The discovery of RNAi has been heralded as a major scientific breakthrough that happens only once every decade or so, and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today.
Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, lifethreatening diseases with limited treatment options for patients and their caregivers.